Polyfunctional T Cell Assay for CMV Infection Risk Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting cytomegalovirus (CMV) infection in transplant recipients are inadequate, leading to overtreatment or undertreatment due to reliance on crude serology and low-sensitivity assays, resulting in significant morbidity and mortality.
Innovation Solution
A method involving the stimulation of T cells with viral antigens in vitro to assess the expression of CD107, IFN-γ, IL-2, and TNF-α, allowing for the determination of a polyfunctional T cell response to predict CMV infection risk and guide prophylactic treatment decisions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If serological testing is used to predict CMV infection risk, then the method is simple and widely applicable, but the prediction precision is low leading to overtreatment or undertreatment
Solution Approach 1:
The patent changes the measurement parameters from simple serological markers to multiple T cell functional markers (CD107a, IFN-γ, IL-2, TNF-α) expressed as percentages. This multi-parameter approach significantly improves prediction precision by capturing the polyfunctional nature of T cell responses, while the standardized scoring system (0-3 scale) maintains practical applicability in clinical settings
Solution Approach 2:
The patent evaluates multiple functions of T cells simultaneously (degranulation via CD107a, cytokine production via IFN-γ, IL-2, and TNF-α) to create a comprehensive risk assessment. This multi-functional evaluation approach improves prediction accuracy by capturing the complex immune response profile, while the unified scoring system maintains methodological simplicity
2Reliability
If prophylaxis is continued indefinitely in D+/R- patients, then the infection prevention is maximized, but the treatment tolerance and patient quality of life deteriorate
Solution Approach 1:
The patent replaces static prophylaxis protocols with dynamic, risk-based decision making. The T cell functional assay provides a time-point assessment that can guide prophylaxis duration, allowing treatment to be adjusted based on individual patient immune status rather than following fixed time-based protocols, thereby improving both reliability and treatment tolerance
Solution Approach 2:
The patent performs preliminary T cell functional assessment to predict future infection risk before making prophylaxis decisions. This advance evaluation allows clinicians to optimize prophylaxis timing and duration, preventing infection in high-risk patients while avoiding unnecessary prolonged treatment in low-risk patients, thus balancing prevention reliability with treatment tolerance
3Reliability
If ganciclovir prophylaxis is administered to all serologically positive recipients, then the infection risk is reduced, but the treatment side effects and patient morbidity increase
Solution Approach 1:
The patent applies different treatment strategies to different patient subgroups based on their T cell functional profiles. By identifying low-risk patients with robust polyfunctional T cell responses, the assay enables targeted prophylaxis only for those who truly need it, reducing unnecessary exposure to ganciclovir side effects while maintaining infection prevention for high-risk individuals
Solution Approach 2:
The patent changes the basis for prophylaxis decision from serological status (binary positive/negative) to functional T cell response parameters (percentages of cells expressing multiple markers). This parameter change enables more precise risk stratification, allowing clinicians to tailor prophylaxis intensity to individual patient needs, thereby reducing overall treatment side effects while maintaining adequate protection
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Methods of evaluating the risk of infection after transplantation or immunosuppression in a subject are provided. Methods of determining whether a subject should be treated prophyiaetically with an anti-microbial agent are also provided herein. Kits for performing the methods described herein are also provided.